Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Treatment of autoimmune diabetes in NOD mice by Toll-like receptor 2 tolerance in conjunction with dipeptidyl peptidase 4 inhibition.

Kim DH, Lee JC, Lee MK, Kim KW, Lee MS.

Diabetologia. 2012 Dec;55(12):3308-17. doi: 10.1007/s00125-012-2723-x. Epub 2012 Sep 27.

PMID:
23011352
2.

Inhibition of autoimmune diabetes by TLR2 tolerance.

Kim DH, Lee JC, Kim S, Oh SH, Lee MK, Kim KW, Lee MS.

J Immunol. 2011 Nov 15;187(10):5211-20. doi: 10.4049/jimmunol.1001388. Epub 2011 Oct 12.

3.

Treatment of autoimmune diabetes by inhibiting the initial event.

Lee MS.

Immune Netw. 2013 Oct;13(5):194-8. doi: 10.4110/in.2013.13.5.194. Epub 2013 Oct 26. Review.

4.

A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis.

Cho JM, Jang HW, Cheon H, Jeong YT, Kim DH, Lim YM, Choi SH, Yang EK, Shin CY, Son MH, Kim SH, Kim HJ, Lee MS.

Diabetes Res Clin Pract. 2011 Jan;91(1):72-9. doi: 10.1016/j.diabres.2010.10.012. Epub 2010 Nov 18.

PMID:
21093089
7.

Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes.

Cabrera SM, Colvin SC, Tersey SA, Maier B, Nadler JL, Mirmira RG.

Clin Exp Immunol. 2013 Jun;172(3):375-82. doi: 10.1111/cei.12068.

8.

Total coumarins from Urtica dentata Hand prevent murine autoimmune diabetes via suppression of the TLR4-signaling pathways.

Wang J, Lu J, Lan Y, Zhou H, Li W, Xiang M.

J Ethnopharmacol. 2013 Mar 7;146(1):379-92. doi: 10.1016/j.jep.2013.01.009. Epub 2013 Jan 20.

PMID:
23340441
9.

Toll-like receptor 7 stimulation promotes autoimmune diabetes in the NOD mouse.

Lee AS, Ghoreishi M, Cheng WK, Chang TY, Zhang YQ, Dutz JP.

Diabetologia. 2011 Jun;54(6):1407-16. doi: 10.1007/s00125-011-2083-y. Epub 2011 Feb 22.

PMID:
21340621
10.

Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor.

Tian L, Gao J, Hao J, Zhang Y, Yi H, O'Brien TD, Sorenson R, Luo J, Guo Z.

Endocrinology. 2010 Jul;151(7):3049-60. doi: 10.1210/en.2010-0068. Epub 2010 May 5.

PMID:
20444936
11.

TLR9 blockade inhibits activation of diabetogenic CD8+ T cells and delays autoimmune diabetes.

Zhang Y, Lee AS, Shameli A, Geng X, Finegood D, Santamaria P, Dutz JP.

J Immunol. 2010 May 15;184(10):5645-53. doi: 10.4049/jimmunol.0901814. Epub 2010 Apr 14.

12.

Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation.

Kim SJ, Nian C, Doudet DJ, McIntosh CH.

Diabetes. 2009 Mar;58(3):641-51. doi: 10.2337/db08-1101. Epub 2008 Dec 10.

13.

The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice.

Jelsing J, Vrang N, van Witteloostuijn SB, Mark M, Klein T.

J Endocrinol. 2012 Sep;214(3):381-7. doi: 10.1530/JOE-11-0479. Epub 2012 Jul 3.

14.

Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells.

Machen J, Harnaha J, Lakomy R, Styche A, Trucco M, Giannoukakis N.

J Immunol. 2004 Oct 1;173(7):4331-41.

15.

The effects of DPP-IV inhibition in NOD mice with overt diabetes.

Vargová L, Zacharovová K, Dovolilová E, Vojtová L, Cimburek Z, Saudek F.

Folia Biol (Praha). 2013;59(3):116-22.

16.

Reduced numbers of dendritic cells with a tolerogenic phenotype in the prediabetic pancreas of NOD mice.

Welzen-Coppens JM, van Helden-Meeuwsen CG, Leenen PJ, Drexhage HA, Versnel MA.

J Leukoc Biol. 2012 Dec;92(6):1207-13. doi: 10.1189/jlb.0312168. Epub 2012 Sep 25.

PMID:
23012431
17.

Curcumin ameliorates autoimmune diabetes. Evidence in accelerated murine models of type 1 diabetes.

Castro CN, Barcala Tabarrozzi AE, Winnewisser J, Gimeno ML, Antunica Noguerol M, Liberman AC, Paz DA, Dewey RA, Perone MJ.

Clin Exp Immunol. 2014 Jul;177(1):149-60. doi: 10.1111/cei.12322.

18.

Thymic stromal lymphopoietin and thymic stromal lymphopoietin-conditioned dendritic cells induce regulatory T-cell differentiation and protection of NOD mice against diabetes.

Besin G, Gaudreau S, Ménard M, Guindi C, Dupuis G, Amrani A.

Diabetes. 2008 Aug;57(8):2107-17. doi: 10.2337/db08-0171. Epub 2008 May 13.

19.

TLR2 signaling improves immunoregulation to prevent type 1 diabetes.

Filippi CM, Ehrhardt K, Estes EA, Larsson P, Oldham JE, von Herrath MG.

Eur J Immunol. 2011 May;41(5):1399-409. doi: 10.1002/eji.200939841.

20.

Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells.

Madec AM, Mallone R, Afonso G, Abou Mrad E, Mesnier A, Eljaafari A, Thivolet C.

Diabetologia. 2009 Jul;52(7):1391-9. doi: 10.1007/s00125-009-1374-z. Epub 2009 May 7.

PMID:
19421731

Supplemental Content

Support Center